Immunohistochemical demonstration of age-related deposition of vitronectin (S-protein of complement) and terminal complement complex on dermal elastic fibers  by Dahlbäck, Karin et al.
Immunohistochemical Demonstration of Age-related 
Deposition of Vitronectin (S-protein of Complement) 
and Terminal 
Elastic Fibers 
Complemeni Complex on Derkal 
Karin Dahlbsck M.D., Helge L&berg, M.D., Ph.D., Jan Alumets, M.D., Ph.D., and 
Bj6rn Dahlb2ck, M.D., Ph.D. 
Departments of Dermatology and Pathology, University of Lund, University Hospital, Lund, and Department of Clinical Chemistry, 
University of Lund, Malmo General Hospital, Malmo, Sweden 
Immunoreactivity of vitronectin was investigated in 100 skin 
specimens from different body regions in 87 individuals of 
different ages using monoclonal and polyclonal anti-vitro- 
nectin antibodies in an avidin - biotin - peroxidase complex 
technique. Vitronectin immunoreactivity was found in con- 
junction with dermal elastic fibers in all subjects older than 
13 years. No vitronectin immunostaining was detected in 
subjects younger than six years, suggesting deposition of vi- 
tronectin during late childhood or early adolesence. Using an 
immunogold staining procedure, vitronectin immunoreac- 
tivity was ultrastructurally localized to the periphery of elas- 
tic fibers. The blood level of vitronectin in 20 healthy new- 
borns was 67% of the adult level, suggesting active 
biosynthesis already in the fetus. To investigate whether vi- 
tronectin is deposited as part of the SC5b-9 complex or as 
uncomplexed protein, the immunoreactivity of vitronectin 
V 
itronectin, also called serum spreading factor, epibo- 
lin, and S-protein of complement, is a multifunctional 
glycoprotein present in plasma and in the extracellu- 
lar matrix [ I- 51. It belongs to a group of cell adhesion 
molecules, all of which mediate adhesion by a com- 
mon Arg- Gly - Asp sequence [6]. Several structurally related cell 
surface receptors for these molecules have been identified [6]. Im- 
mobilized vitronectin induces spreading of cultured fibroblasts and 
stimulates migration of tumor cells [7,8]. 
Soluble vitronectin inhibits the membrane attack complex 
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APAAP: alkaline phosphatase anti-alkaline phosphatase 
C: complement protein 
C5b-9: complex of complement proteins C5b, C6, C7. C8, and C9 
MAC: membrane attack complex 
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SC5b-9: complex of complement proteins C5b, C6, C7, C8, C9, 
and S-protein (vitronectin) 
was compared with that of C9, using monoclonal and poly- 
clonal antibodies against the C9 neoantigen. Distinct C9 
neoantigen immunoreactivity was demonstrated in associa- 
tion with dermal elastic fibers in human skin in adults but 
only in subjects older than 30 years. The intensity of C9 
neoantigen immunoreactivity appeared to increase with age 
and was found to be stronger in sun-exposed skin than in 
sun-protected skin. These findings indicate that uncom- 
plexed vitronectin is deposited during childhood or early 
adolescence and that terminal complement complexes 
(C5b-9 and/or SC5b-9) are deposited on elastic fibers later on 
in life. Hypothetically, the tissue form of vitronectin may be 
involved in the prevention of tissue damage in proximity to 
local complement activation. In addition, it may be physio- 
logically important as substratum for cells, stimulating cell 
migration and anchorage. JInvestDermatol92:727- 733,1989 
(MAC) of the complement pathway [9]. The MAC is formed 
through the assembly of the complement proteins C5, C6, C7, C8, 
and C9 (C5b-9) on a cell surface and results in membrane damage 
[lo]. In the fluid phase, a water soluble, nonlytic complex (the 
SC5b-9 complex) is formed as a result of the association of vitronec- 
tin (S-protein of complement) with the forming C5b-9 complex 
[9,10]. 
Plasma vitronectin may also have regulatory functions in the 
coagulation system. It binds to heparin, inhibits the thrombin- 
antithrombin III reaction, and during coagulation it is incorporated 
into a ternary complex with thrombin and antithrombin III [ll- 
141. Platelets and endothelial cells adhere to vitronectin, indicating 
that vitronectin may play a role in platelet aggregation and 
thrombus formation [15,16]. 
Neoantigens of C9 are exposed during the formation of both 
MAC and SC5b-9 [17]. S everal monoclonal and polyclonal anti- 
bodies specific for such neoantigens have been characterized. These 
reagents distinguish between native C9 and C9 in MAC or SC5b-9, 
but not between C9 in MAC and the SC5b-9 complex. Antibodies 
specific for the C9 neoantigens have been used to demonstrate C9 
immunoreactivity in several diseases [ 18 - 261. 
We have found vitronectin immunoreactivity in close association 
with normal elastic tissue in skin and kidney in adults [27,28]. It is 
also recently reported to be associated with elastic fibers in lamina 
muscularis mucosae of the human colon and in s ecimens of aorta 
with and without signs of arteriosclerosis [23,26 P . Our findings of 
vitronectin immunoreactivity in such degenerative lesions as neph- 
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rosclerosis, amyloidosis, and solar elastosis prompted us to investi- 
gate the distribution of vitronectin in skin of different ages [28,29]. 
To determine whether tissue vitronectin is deposited as part of 
MAC/SC5b-9 or as uncomplexed protein, vitronectin immunore- 
activity was compared with that of C9, using antisera specific for ~9 
neoantigen. 
MATERIALS AND METHODS 
Biological Tissue Skin sam les were obtained when surrounding 
normal skin was trimmed o ffp excision biopsies (55 specimens), at 
autopsy (5 specimens), and from surgical circumcisions (14 speci- 
mens). The autopsy specimens were obtained within 2 dafter death. 
Vitronectin immunoreactivity was unchanged during this time (un- 
published observation). In addition, skin biopsies were obtained 
from 13 voluntary subjects ranging in age from 39 to 80 years, from 
both sun-exposed skin (extensor forearm or neck) and from sun- 
protected skin (axilla or groin). In total 100 skin specimens from 
several different body regions were obtained from 87 individuals, 
ranging in age from 24 wk in utero to 80 years (Table I). The 
specimens were stained with standard elastin staining procedure 
using orcein. They were from nonlesional skin, except for IO, 
which had clinical and histologic signs of elastosis. These specimens 
were from sun-exposed skin regions in subjects over 58 years of age. 
The skin specimens used for electron microscopy were taken 
from the axilla and the trunk of middle-aged subjects. 
Fixation Procedure 
Light Microscopy The specimens were either instantly frozen in 
chlordifluormethane R22 at the temperature of liquid nitrogen or 
immersed in a transport medium (550 g ammonium sulphate added 
to 1 L 25mM potassium citrate, 5 mM N-ethylmaleimide, 5 mM 
magnesium sulphate), washed within 48 h in transport medium 
lacking ammonium sulphate and then frozen. The two ways of 
handling the specimens gave the same final results. All specimens 
were stored at -70°C until processed. Cryostat sections, between 
4- lo-pm thick, were fixed in acetone for 20 min at 4”~. Some of 
the specimens were also processed unfixed. This gave the same 
results as when acetone fixation was used. 
Electron microscopy Skin specimens were fixed in 3% paraformalde- 
hyde, 1% glutaraldehyde in 0.075M phosphate buffer overnight, 
rinsed in the same buffer, dehydrated, and block contrasted. They 
were then infiltrated with Lowicryl K4M (Chemische Werke 
Lowi, Waldkrailburg, Germany) and placed in capsules that were 
filled with fresh Lowicryl[3O]. Initial polymerization with ultravi- 
olet light (360 nm) was for 2 d at -25°C. Ultraviolet polymeriza- 
tion was continued for 2 d at room temperature. 
Ultrathin sections were collected on formvar-coated gold grids 
before being treated with primary and secondary antibodies. 
Proteins and Primary Antisera Vitronectin was isolated from 
human plasma as described by Dahlbkk and Podack [31]. A specific 
Table 1. Age Distributions and Biopsy Sites in 87 Subjects 
Skin o-5 6-10 11-20 21-30 31-50 51-85 
region (Yr) (Yr) (Yr) (Yr) (Yr) (Yr) 
Prepuce 5 5 4 
Axilla 1 5* 5’ 
Groin 1 1 3f 
Glute 1 1 
Trunk 5 5 3 3 4 
chest 2 3 2 
Back 7 7 2 
Thigh 1 1 1 1 
Knee 1 
Forearm 5* 9(7*) 
Neck 1 W’) 
Face 2 2 
III 13 of the subjects (*) biopsies were taken from both sun-exposed (forearm, neck) 
and son-protected (axilla. groin) skin. 
rabbit polyclonal anti-vitronectin antiserum, earlier characterized 
in detail, was used [27]. A mouse monoclonal antibody against vi- 
tronectin [called S-protein at Cytotech) was a kind gift of Dr Ta- 
merius at Cytotech, San Diego, CA. 
The C9 was isolated from human plasma [32]. The isolated C9 
was polymerized using Zn ++ [33]. Rabbits were immunized with 
the polymerized C9 using standard procedures. To obtain an anti- 
serum specific for the neoantigens exposed after C9 polymerization, 
it was passed over a column with plasma coupled to CNBr-activated 
sepharose. Monoclonal antibody against C9 neoantigen was the 
kind gift of Dr T C Mollnes, Department of Immunology, Riksho- 
spitalet, Oslo, Norway [22]. Unless otherwise stated, the working 
dilution used in the immunohistochemical experiments was 
1:30,000 (monoclonal anti-C9 neoantigen), 1:400 (polyclonal anti- 
C9 neoantigen), l:lO,OOO ( monoclona1 
1:20,000 (polyclonal anti-vitronectin). 
anti-vitronectin), and 
Sequence-specific rabbit antiserum against amyloid A protein 
(working dilution 1:50) used as negative control was a kind gift of 
Dr A Grubb, Department of Clinical Chemistry, Maims General 
Hospital, Malmb, Sweden. Polyclonal antiserum against serum 
amyloid P component (working dilution 1:3000) was obtained 
from Dakopatts a/s Copenhagen (Copenhagen, Denmark) and goat 
antirabbit IgG labeled with 10 nm colloid gold particles (working 
dilution l:lO), was obtained from Peninsula Laboratories Europe 
Ltd., St. Helens, U.K. 
Antiserum Control Procedures The specificities of the anti-vi- 
tronectin antibodies were tested as described in earlier reports [27]. 
The C9 antiserum gave a strong and specific reaction with purified 
C9, polymerized C9, and with C9 in plasma when analyzed with 
Western blotting [34]. In immunelectrophoresis, it gave no im- 
munoprecipitate when tested against whole human plasma or native 
C9, demonstrating its specificity against the C9 neoantigen. The 
specificities of the antisera- tissue subcomponent reactions in the 
avidin-biotin peroxidase complex technique were also checked by 
absorption experiments. Aliquots (100 ~1) of the two C9 antisera 
and of anti-vitronectin diluted in phosphate-buffered saline (PBS) 
containing 2.5% bovine serum albumin to their respective working 
dilutions, were incubated overnight with increasing amounts of 
purified polymerized C9 (0.003-0.3 pg) or vitronectin (O.OOl- 
lO$g). In these adsorption experiments, no cross-reactivity was 
found between the anti-C9 and the anti-vitronectin antisera. The 
anti C9 staining, whether obtained with polyclonal or monoclonal 
antibodies, remained unaffected even by the highest amount of 
vitronectin tested; similarly the anti-vitronectin staining was unaf- 
fected by C9. The anti-C9 staining obtained both with the mono- 
clonal and the polyclonal antisera was partly and completely inhib- 
ited by 0.03 and 0.3 pug purified C9, respectively. 
Immunohistochemical Techniques 
Light Microscopy All the specimens were processed with polyclonal 
and monoclonal anti-C9 neoantigen antibodies and with polyclonal 
anti-vitronectin antiserum. The specimens from subjects younger 
than 13 years of age and selected specimens from different body 
regions in adults were also processed with the monoclonal anti-vi- 
tronectin antibodies. Specific rabbit antiserum against amyloid A 
protein was used as the negative control on all specimens. 
The avidin-biotin peroxidase complex technique was used as 
described by Hsu et al [35] with biotinylated goat anti-rabbit or 
horse anti-mouse antiserum as the secondary antiserum and 3.3’-di- 
aminobenzidine as the peroxidase substrate. The alkaline phospha- 
tase anti-alkaline phosphatase (APAAP) complex technique, using 
naphtol-As-Mx phosphate/Fast Blue as the alkaline phosphatase 
substrate, was performed as described [36]. Chicken anti-mouse 
immunoglobulin was used as the secondary antiserum in the proce- 
dure. 
The intensity of immunoreactivity was estimated by one or two 
observers using an arbitrary scale of gradually increasing values from 
0 (negative) to 3 (strong). Staining intensity was assigned 1.5 when 
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estimated to be definitly positive, 1 when weak, and 0.5 when 
barely detected. The mean of the two values obtained with mono- 
clonal and polyclonal antibodies was used when analyzing the re- 
sults. The polyclonal and the monoclonal antibodies generally gave 
similar results; the differences only in a few cases exceeding 0.5. 
Some of the specimens were studied with a sequential immuno- 
staining procedure as follows: in the first reaction, monoclonal anti- 
C9 neoantigen or monoclonal anti-vitronectin was used in the 
APAAP complex technique, producing a blue color on the immu- 
noreactive structures. After photography, the slides were left in 
50 mMTris-HCL0.15 MNaCl,pH 7.5, for 12 hat 37°C todetach 
the co’verslips. The slides were then treated with xylol for 3 min at 
room temperature, a procedure that removed the blue color but did 
not affect the immunoreactivity in the subsequent reaction. In the 
second reaction, the sections were incubated with either polyclonal 
anti-vitronectin or polyclonal anti-C9 neoantigen antibodies and 
developed with th e avidin- biotin-peroxidase technique, which 
stains the immunoreactive structures brown. Orcein staining was 
used as the second reaction. Negative controls for the second reac- 
tion were either PBS or the anti-amyloid A antiserum. This sequen- 
tial staining technique made it possible to compare the distributions 
of the anti-C9 neoantigen and the anti-vitronectin immunoreactiv- 
ities in the same tissue section. 
Methyl green, 2% (Certistain, Merck Downstudt, Germany), 
was used on sections after the avidin-biotin peroxidase complex 
staining procedure to visualize epidermal and dermal cells. 
Electron Microscopy Ultrathin sections were treated either with pol- 
yclonal anti-vitronectin (working dilution 1:lOOO) or with poly- 
clonal anti-serum amyloid P component overnight, rinsed in PBS, 
treated with gold-coated secondary antibodies for 1 h, and carefully 
rinsed [37]. The specificity was checked by omitting the primary 
antibody. Grids were stained in 1% uranyl acetate for 20 min and 
with 0.5% lead citrate for 5 min before examination in a JEOL 200 
CX electron microscope. 
Determination of Plasma Vitronectin Concentration Im- 
mediately after delivery, blood from 20 healthy newborns was col- 
lected in l/10 vol of 129 mM trisodium citrate. The blood was 
taken from the umbilical vein of the cord, which was double- 
clamped before placental separation. The samples were immedi- 
ately centrifuged and the plasma stored at -20°C until analyzed. 
The plasma concentrations of vitronectin was determined by elec- 
troimmunoassay run at 80 V overnight in buffer containing ethy- 
lenediaminetetraacetic acid [38]. Pooled titrated plasma from 20 
healthy adult blood donors was used as standard. The standard was 
diluted from l/5 to l/40 in 50 mM Tris-HCl, pH 7.5, 0.15M 
NaCl. The plasma samples from the infants were diluted l/15. 
RESULTS 
Specimens from different body regions in individuals of different 
ages, including the very young, demonstrated a dermal fiber net- 
work stainable with orcein. Specimens from young subjects gener- 
ally had fine delicate elastic fibers that were thicker and more irreg- 
ular with increasing age as described by others [39]. Ten of the 
specimens, which were from sun-exposed skin in older subjects had 
distinct signs of solar elastosis with a so-called grenz zone under the 
dermal- epidermal junction area and curled, irregular elastic fibers. 
Vitronectin immunoreactivity was invariably detected in con- 
junction with elastic fibers in specimens from individuals older than 
Figure 1. Skin specimens immunostained in an avidin-biotin peroxidase complex technique with polyclonal anti-vitronectin antibodies (a,&,~) and with 
monoclonal anti-C9 neoantigen antibodies (d,e,jj. a,d; Sk’ in f rom preputium of Z-year-old. b,e; Skin from back of 17-year-old subject. c,j Skin from back of 
48-year-old subject. Epidermis visualized by staining cells with methyl green (bar: 20 pm). 
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Table II. Mean Score of Intensity of Vitronectin and C9 
Immunoreactivity in 100 Skin Specimens 
Age (yr) No biopsies 
O-5 11 
6-10 10 
11-20 19 
21-30 8 
31-50 24 
51-85 28 
Vitronectin 
0 (O-O) 
0.5 (O- 1.5) 
2.1 (O-3) 
3 (2.5-3) 
C9 neoantigen 
0 (O-O) 
0 (O-O) 
0.1 (O-0.7) 
0.7 (O- 1) 
1.4 (0.5-2.25) 
1.8 (0.5-31 
Range in brackets. Intensity of immunoreactivity measured by an arbitrary scale of 
gradually increasing values from 0 (negative) to 3 (strong). 
13 years, but was absent in specimens from subjects younger than six 
years. In samples obtained from subjects between six and 13 years of 
age, vitronectin immunoreactivity was weakly detected in six of 14 
cases. All specimens from subjects over 20 years ofage demonstrated 
strong immunostaining (Fig 1 a-c and Table II). Elastotic material 
was immunostained with anti-vitronectin in agreement with an 
earlier report [29]. Essentially identical results were obtained with 
the polyclonal and monoclonal anti-vitronectin antibodies. There 
was no vitronectin or ~9 neoantigen immunostaining of the epi- 
dermis, dermal- epidermal junction area, or dermal collagen fibers. 
Ultrastructurally the immunoreactivity of vitronectin was found to 
be localized at the periphery of the elastic fibers, corresponding with 
the localization of amyloid P component immunoreactivity (Fig 2). 
Specific ~9 neoantigen immunoreactivity was absent or faint in 
specimens from subjects younger than 30 years, but was found in 
conjunction with dermal elastic fibers in individuals over 35 years of 
age (Fig 1 d-f). Th e intensity of C9 reactivity on the elastic fibers 
tended to increase with age (Table II). It also tended to be stronger 
in specimens from sun-exposed body regions than in specimens 
from sun-protected regions. No C9 neoantigen immunoreactivity 
could be demonstrated in specimens from sun-protected areas in 
subjects younger than 58 years. It was detected in three of six speci- 
mens from sun-protected skin of subjects older than 58 years (Table 
III). When compared in the same individual, the intensity of C9 
neoantigen immunoreactivity was found to be fainter in sun-pro- 
tected than in sun-exposed skin (Fig 3 and Table III). Elastotic 
material was immunostained with anti-C9 neoantigen but the 
staining was generally fainter than that of vitronectin. All speci- 
mens were studied with both monoclonal and polyclonal anti-C9 
neoantigen antibodies and they gave essentially identical results. 
Using a sequential immunostaining technique it could be demon- 
strated that the same fibers were stained with anti-C9 neoantigen as 
with anti-vitronectin, thus being elastic fibers (Fig 4). 
The concentration of vitronectin in plasma obtained from the 
umbilical blood of 20 healthy newborns was determined to be 
67.3 f 9.3% (mean + SD) of the adult value. 
DISCUSSION 
The detection of vitronectin immunoreactivity on the dermal elas- 
tic fibers in all specimens from subjects over 13 years of age and its 
absence in skin specimens from younger children indicates an age- 
related deposition of vitronectin on these fibers during late child- 
hood or early adolescence. The absence of vitronectin immunoreac- 
tivity in elastic fibers in the young indicates that vitronectin is not a 
constituent part of the elastic fibers before the age of 6 years. In this 
context, a noteworthy finding was that the concentration of vitro- 
nectin in plasma from umbilical blood was approximately 67% of 
the adult level, suggesting active biosynthesis already in the fetus. 
The ultrastructural localization, corresponding with that of serum 
amyloid P component, suggests association of vitronectin with the 
Figure 2. Electron micrographs of a section of sun-protected skin from middle-aged subject stained with immunogoid labelmg technique using polyclonal 
anti-vitronectin antibodies demonstrating labeling at the perifery of two elastic fibers (bar: 140 nm). 
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Table III. Intensity of Immunoreactivity of C9 Neoantigen and Vitronectin in Sun-exposed and Sun-protected Skin 
From Same Individual 
Years of age 
38 41 44 45 48 55 57 58 59 60 73 80 80 
C9-neoantigen 
Sun-protected skin 0.3 0.5 0.5 1 0.5 0.5 0.25 1.75 1.5 1.25 1.25 1.5 1.25 
Sun-exposed skin 1 1.5 2 2.25 2.25 2 2 2.25 1.5 2.25 2.25 2.5 2.25 
Vitronectin 
Sun-protected skin 3 3 2.5 3 3 3 3 3 3 3 3 3 3 
Sun-exposed skin 3 3 3 3 3 3 3 3 3 3 3 3 3 
Intensity of immunoreactivity measured by an arbitrary scale of gradually increasing values from 0 (negative) to 3 (strong). 
Subjects over 58 years of age with signs of elastosis in sun-exposed skin. 
periphery of the elastic fibers. Immunoreactivity of serum amyloid 
P component has been reported to be localized in conjunction with 
elastin associated microfibrils [JO]. It was not possible to judge from 
the micrographs whether vitronectin immunoreactivity was asso- 
ciated with the surface of the amorphous elastin or with the elastin- 
associated microfibrils. 
The C9 neoantigen immunoreactivity was also found in conjunc- 
tion with dermal elastic fibers but only in middle-aged and older 
individuals, and tended to increase with age. These results indicate 
that uncomplexed vitronectin is deposited initially on the elastic 
fibers. Vitronectin immunoreactivity without co-localized immu- 
noreactivity of c-9 neoantigen has been observed earlier in the 
submucosa of colon and in aorta, supporting the suggestion that 
uncomplexed vitronectin is deposited in normal tissue [23,26]. 
Immunoreactivity of C9 neoantigen in conjunction with dermal 
elastic fibers has not been reported previously, although immuno- 
histochemical studies have been done on human skin using anti-C9 
neoantigen antibodies in studies on lupus erythematosus, leukocy- 
toclastic vasculitis, dermatitis herpetiformis, and pemphigoid [ 18 - 
211. This may be because the specimens studied were from sun-pro- 
tected skin areas or from young subjects. Moreover, the use of 
immunofluorescence techniques in those studies may have in- 
fluenced the results. Elastin demonstrates some autofluorescence 
that may be difficult to eliminate despite the use of appropriate 
filters. Therefore, specific C9 immunoreactivity on elastic fibers 
may be overlooked as being the effect of autofluorescence. The use 
of an avidin-biotin eroxidase technique in this study eliminated 
these potential prob ems. The use of both monoclonal and poly- P 
clonal antibodies corroborated the specificities of the reactions as 
did cross adsorption experiments with purified C9 and purified 
vitronectin. 
The molecular status of the C9 deposited in middle age and later 
in life is unknown. Hypothetically, terminal complement com- 
plexes forming in the vicinity of elastic fibers may bind to the elastin 
associated vitronectin. It is at present unknown whether the tissue 
form of vitronectin, like its soluble counterpart in plasma, can in- 
Figure 3. Skin specimens from sun-protected (u,b) and sun- 
exposed (c,d) regions in a 40-year-old (u,c) and an 80-year-old 
(b,d) individual, immunostained in an avidin- biotin peroxidase 
complex technique with monoclonal anti-C9 neoantigen anti- 
bodies. Epidermis visualized by staining cells with methyl green 
(bar: 20 pm). 
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Figure 4. Specimens from sun-exposed skin in subjects, 50-year-old (u,c) and 80-y ear-old (b,d) stained in a sequential immunostaining rocedure. The same 
section was immunostained with monoclonal anti-vitronectin antibodies (a,b) and with polyclonal anti-C9 neoantigen antibodies (c, ). Eprdermrs stained B 
with methyl green in c and d (bar: 20 pm). 
hibit the formation of the MAC. An alternative explanation for the 
elastin associated C9 immunoreactivity may be a deposition of solu- 
ble SCSb-9 complexes on elastin fibers. 
The findings of C9 neoantigen immunoreactivity predominantly 
in sun-exposed skin suggest that sun exposure may influence its 
deposition. The UVA-induced activation of the complement sys- 
tem has been reported in cases with erythropoietic protoporphyria, 
porphyria cutanea tarda, and in hematoporphyrin and chlorproma- 
zine phototoxicity, but not in healthy subjects [41,42]. Data sug- 
gesting involvement of the complement system in UVB-induced 
inflammation have been presented recently [43]. 
Elastin-associated vitronectin may be an important substratum for 
migrating cells with vitronectin receptors and may be involved in 
the anchorage of certain cells in the tissue. presumably such cells 
would be protected from lysis due to complement activation by the 
ability of vitronectin to inhibit MAC. Several cell types (e.g., neu- 
trophilic polymorphonuclear leukocytes, macrophages, and fibro- 
blasts) have elastase-type proteases and thus tissue vitronectin may 
play a role in the protection of the elastin fiber [44]. Several ty es of 
bacteria have been demonstrated to bind vitronectin, possibly P acili- 
tating invasion in the host tissue [45]. Co-localization of invading 
bacteria with leukocytes and macrophages on the elastic fibers may, 
on the other hand, facilitate the phagocytosis of the bacteria and 
thus, the tissue form of vitronectin, may be an important factor in 
host defense. 
The authors thank Vinca Filinic, Anette Larsson, Anne Ljungquist, Lena Sandell, 
andlngrid Olofssonfor expert technical assistance; Dr. T. E. Mollnesfor his kindgift 
of the monoclonal anti-C9 neoantigen antibody, Dr. John Tamarius at Cytotech, San 
Diego,& his kindgiJt of the monoclonal anti-vitronettin antibody, and Dr. Anders 
Grubbfor the anti-AA antibody The valuablesupport of Pro&or Hans Rorsman is 
oratefully acknowledged. 
REFERENCES 
1. Holmes R: Preparation from human serum of an alpha-one protein 
which induces the immediate growth of unadapted cells in vitro. J 
Cell Biol 32:297-308, 1967 
2. Barnes D, Wolfe R, Serrero G, McClure D, Sato G: Effects of a serum 
spreading factor on growth and morphology of cells in serum-free 
medium. J Supramol Struct 14:47-63, 1980 
3. Hayman EG, Pierschbacher MD, Bhrgren Y, Ruotslahti E: Serum 
spreading factor (vitronectin) is present at the cell surface and in 
tissues. Proc Nat1 Acad Sci USA 80:4003 - 4007, 1983 
4. Jenne D, Stanley KK: Molecular cloning of S-protein, a link between 
complement, coagulation and cell-substrate adhesion. EMBO J 
4:3153-3157, 1985 
5. Stenn KS: Coepibolin, rhe activity of human serum that enhances the 
cell spreading properties of epibolin, associates with albumin. J In- 
vest Dermatol 89:59-63, 1987 
VOL. 92. NO. 5 MAY 1989 VITRONECTIN AND C9 NEOANTIGEN ON ELASTIC FIBERS 733 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
Ruoslahti E, Pierschbacher MD: New perspectives in cell adhesion: 
RGD and integrins. Science 238491-497, 1987 
Barnes DW, Silnutzer J, See C, Shaffer M: Characterization of human 
spreading factor with monoclonal antibody. Proc Nat1 Acad Sci 
USA 80:1362-1366,1983 
Basara ML, McCarthy JB, Barnes DW, Furcht LT: Stimulation of 
haptostaxis and migration of tumour cells by serum spreading factor. 
Cancer Res 45:2487 -2494, 1985 
Podack ER, Preissner KT, Muller Eberhard HJ: Inhibition of C9 poly- 
merisation within the SC5b-9 complex of complement by S-pro- 
tein. Acta Path01 Microbial Immunol Stand (C) (Suppl) 284 
(92):889-896, 1984 
Muller-Eberhard HJ: The killer molecule of complement. J Invest 
Dermatol 85:47-52, 1985 
Ill Cr. Ruoslahti E: Association ofthrombin-antithrombin III complex 
with vitronectin in serum. J Biol Chem 260:15610-15615, 1985 
Jenne D, Hugi F, Bhakdi S: Interaction of complement S-protein with 
thrombin-antithrombin complexes: a role for the S-protein in hae- 
mostais. Thromb Res 38:401-412, 1985 
Podack ER, Dahlback B, Griffin J: Interaction of S-protein of comple- 
ment with thrombin and antithrombin III during coagulation. J Biol 
Chem 261:7387-7392,1986 
Preissner KT, Muller-Berghaus G: S-protein modulates the heparin- 
catalyzed inhibition of thrombin by antithrombin III. Eur J Bio- 
them 156:654-650, 1986 
Asch E, Podack E: S protein binds to activated platelets and mediates 
aggregation. Abstracts XII International Complement Workshop, 
September 18-21, Chamonix, France. Karger, 1987, p 129. 
Preissner KT, Anders E, Muller-Berghaus G: Specific interaction of 
complement S-protein/vitronectin with cultured endothelial cells. 
Abstracts XII International Complement Workshop, September 
18-21, Chamonix, France. Karger, 1987, p 213. 
Kolb, WP, Muller-Eberhard HJ: Neoantigens of the membrane attack 
complex of human complement. Proc Nat1 Acad Sci USA 72: 1687, 
1975 
Biesecker G, Lavin L, Ziskind M, Koffler D: Cutaneous localization of 
the membrane attack complex in discoid and systemic lupus ery- 
thematosus. N Engl J Med 306:264-270, 1982 
Dahl MV, Falk RJ, Carpenter R, Michael A. Deposition of the mem- 
brane attack complex of complement in bullous pemphigoid. J In- 
vest Dermatol 82:132- 135, 1984 
Dahl MV, Falk RJ, Carpenter R, Michael A: Membrane attack com- 
plex of complement in dermatitis herpetiformis. Arch Dermatol 
121:70-72,1985 
Boom BW, Out-Luiting CJ, Baldwin WM, Westedt M-L, Daha MR, 
Vermeer B-J: Membrane attack complex of complement in leuko- 
cytoclastic vasculitis of the skin. Arch Dermatol 123:1192- 1195, 
1987 
Mollnes TE, Harboe M: Immunohistochemical detection of the mem- 
brane and fluid-phase terminal complement complexes C5b-9 (m) 
and SC5b-9. Stand J Immunol26,381-386.1987 
Halstensen TS, Mollnes TE, Garred P, Brandtzaeg P: Distribution of 
terminal complement complex and S-protein (Vitronectin) in nor- 
mal and inflamed human colon. Abstracts XII International Com- 
plement Workshop, September 18 -21, Chamonix, France. Karger, 
1987, p 164. 
Falk RJ, Podack E, Dalmasso AP, Jennette JC: Localization of S pro- 
tein and its relationship to the membrane attack complex of comple- 
ment in renal tissue. Am J Path01 127:182- 190, 1987 
Biesecker G, Katz S, Koffler D. Renal localization of the membrane 
attack complex in systemic lupus erythematosus nephritis. J Exp 
Med 154:1779- 1794.1981 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
39. 
40. 
41. 
42. 
43. 
44. 
45. 
Niculescu F, Rus HG, Vlaicu R: Immunohistochemical localizationof 
C5b-9, S-protein, C3d and apolipoprotein B in human arterial tis- 
sues with arteriosclerosis. Arteriosclerosis 65:1- 11, 1987 
Dahlback K, Lotberg H, Dahlback B: Localization of vitronectin (S- 
protein of complement) in normal human skin. Acta Derm Venereol 
(Stockh) 66:461-467, 1986 
Dahlback K, L&erg H, Dahlback B: Immunohistochemical demon- 
stration of vitronectin in association with elastin and amyloid de- 
posits in human kidney. Histochemistry 87:511-515, 1987 
Dahlback K, L&berg H, Dahlback B: Immunohistochemical studies of 
vitronectin in elastic tissue disorders, cutaneous amyloidosis, lichen 
ruber planus and porphyria. Acta Derm Venerol (Stockh) 68:107- 
115, 1988 
Roth J, Bendayan M, Carlemalm E, Villiger W, Garavito M: Enhance- 
ment of structural preservation and immunocytochemical staining 
in low temperature embedded pancreatic tissue. J Histochem Cyto- 
them 29,663-671,198l 
Dahlbkk B, Podack ER: Characterization of human S protein, an 
inhibitor of the membrane attack complex of complement. Demon- 
stration of a free reactive thiol group. Biochemistry 24:2368-2374, 
1985 
Biesecker G, Muller-Eberhard HJ: The ninth component of human 
complement: Purification and physiochemical characterization. J 
Immunol 124:1291-1296,198O 
Tschopp J: Circular polymerization of the membranolytic ninth com- 
ponent of complement. J Biol Chem 259:10569-10573.1984 
Burnette WN. “Western blotting” electrophoretic transfer ofproteins 
from sodium dodecyl sulfate-polyacrylamide gels to unmodified 
nitrocellulose and radiographic detection with antibody and ra- 
dioiodinated protein A. Anal Biochem 112:195-203, 1981 
Hsu SM, Raine L, Fanger H: A comparative study of the peroxidase - 
antiperoxidase method and an avidin-biotin complex method for 
studying polypeptide hormones with radioimmuinoassay antibod- 
ies. Am J Clin Path01 75:734-738, 1981 
Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Macdonald 
S, Pulford KAF, Stein H, Mason DY: Immunoenzymatic labeling 
monoclonal antibodies using immune complexes of alkaline phos- 
phatase and monoclonal anti-alkaline phosphatase (APAAP com- 
plexes) J Histochem Cytochem 32:219-229, 1984 
Valentino KL, Crumrine DA, Reichardt LF: Lowicryl K4M embed- 
ding of brain tissue for immunogold electron microscopy. J Histo- 
them Cytochem 33:969-973.1985 
Laurel1 CB: Electroimmunoassay. Scan J Clin Lab Invest 29 (Suppl 
124):21-37, 1972 
Montagna W, Carlisle K: Structural changes in aging human skin. J 
Invest Dermatol 73:47 - 58, 1979 
Breathnach SM, Melrose SM, Bhogal B, deBeer FC, Black MM, Pepys 
MB: Immunohistochemical studies of amyloid P component distri- 
bution in normal human skin. J Invest Dermatol 80:86-90, 1983 
Lim HW, Gigli I: Role of complement in porphyrin-induced photo- 
sensitivity. J Invest Dermatol 76:4-9, 1981 
Torinuki W, Tagami H: Role of complement in chlorpromazine-in- 
duced phototoxicity. J Invest Dermatol 86:142-144, 1985 
Torinuki W, Tagami H: The role of complement in UVB-induced 
inflammation UVB-complement. Acta Derm Venereol (Stockh) 
66:386- 390.1986 
Frances C, Robert L: Elastin and elastic fibers in normal and pathologic 
skin. Int J Dermatol 23:166- 178, 1984 
Chhatwal GS, Preissner KT, Muller-Berghaus GM, Blobel H: Specific 
binding of the human S protein (Vitronectin) to streptococci, Sraph- 
ylocorcus (~ureus and Escherichia co/i. Infect Immun 55:1878-1883, 
1987 
